Results 41 to 50 of about 1,925 (192)

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

Acta Paediatrica, EarlyView.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner, Despina D. Briana, Gian Carlo Di Renzo   +2 more
wiley   +1 more source

Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in Oceania

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Autosomal recessive interferon alpha and beta receptor subunit 1 (IFNAR1) deficiency is a rare and heritable inborn error of immunity (IEI) predisposing individuals to severe and life‐threatening viral infections. It is more common in people of Western Polynesian ancestry, with estimates of around one in six thousand live births affected, due ...
Cecilia Verryt, Paul Gray, Peter McNaughton, Jane Peake, Melanie Wong, George Aho, Emma Best, Maia Brewerton, Flora Lutui, Litara Esera Tulifau, Rebecca Qin, Satupa‘itea Viali, Petine White, Andrew Wood, See‐Tarn Woon, Theresa Cole, Alberto Pinzon Charry, Kuang‐Chih Hsiao   +17 more
wiley   +1 more source

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysisResearch in context

The Lancet Regional Health. Americas
Summary: Background: In August 2023, the Centers for Disease Control and Prevention recommended nirsevimab, a long-acting monoclonal antibody, for all U.S. infants aged
Amanda B. Payne, Steph Battan-Wraith, Elizabeth A.K. Rowley, Melissa S. Stockwell, Sara Y. Tartof, Kristin Dascomb, Stephanie A. Irving, Brian Dixon, Sarah W. Ball, Mark W. Tenforde, Gabriela Vazquez-Benitez, Ashley B. Stephens, Jungmi Han, Karthik Natarajan, S. Bianca Salas, Cassandra Bezi, Lina S. Sy, Bruno Lewin, Tamara Sheffield, Julie Arndorfer, Daniel Bride, Josh Van Otterloo, Allison L. Naleway, Padma D. Koppolu, Shaun Grannis, William Fadel, Colin Rogerson, Tom Duszynski, Sarah E. Reese, Patrick K. Mitchell, Sean Chickery, Heidi L. Moline, Morgan Najdowski, Allison Avrich Ciesla, Emily L. Reeves, Malini DeSilva, Katherine E. Fleming-Dutra, Ruth Link-Gelles   +37 more
doaj   +1 more source

Respiratory Syncytial Virus Under the Lens of Structure: From Prefusion Stabilization to Next‐Generation Immunotherapies

iNew Medicine, Volume 2, Issue 2, June 2026.
This illustration integrates key concepts covered in the review, including high‐risk populations, viral structure, host entry factors, the replication cycle, and licensed antibody‐based prevention strategies. ABSTRACT Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae.
Zekai Cheng, Qianqian Wang, Jiachen Zhang, Sandra Chiu   +3 more
wiley   +1 more source

Potential for Nirsevimab use in Pakistan

Journal of the Pakistan Medical Association
Respiratory Tract Infections can be classified as upper and lower tract infections. Upper tract infections are more common such as laryngitis and pharyngitis, but the infections of lower respiratory tract are more fatal such as influenza or bronchitis.
Muhammad Moaz, Basum Hayat
openaire   +3 more sources

Impact of Respiratory Viral Codetections on RSV Disease Burden in Young Children in Primary Care

Influenza and Other Respiratory Viruses, Volume 20, Issue 6, June 2026.
ABSTRACT Background Young children with respiratory syncytial virus (RSV) often have viral coinfections. This study assessed the impact of respiratory viral codetections on RSV disease burden in children < 5 years and whether this varies by specific codetected viruses.
Levi Duijst, Valérie Sankatsing, Caterina Rizzo, Francesco Baglivo, Elizabeth Button, Marta Carballal Mariño, María Garcés Sánchez, Christine Hagemann, Simon de Lusignan, Oliver Martyn, Marc Raes, Daan Van Brusselen, Joanne Wildenbeest, Sarah Hak, Foekje Stelma, Jojanneke van Summeren, on behalf of the RSV ComNet network   +16 more
wiley   +1 more source

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

Human Vaccines & Immunotherapeutics
The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal ...
Annefleur C. Langedijk, Floris van den Dungen, Lisette Harteveld, Jennie van den Boer, Lucy Smit, Ahuva Averin, Erin Quinn, Mark Atwood, Amy Law, Diana Mendes, Marlies van Houten   +10 more
doaj   +1 more source

Reduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany

Influenza and Other Respiratory Viruses, Volume 20, Issue 6, June 2026.
ABSTRACT After introducing nirsevimab during the 2024/2025 respiratory syncytial virus (RSV) season in Germany, RSV activity in infants under 1 year dropped by 50% in primary care and 50%–70% in secondary care. Inpatients under 6 months showed the greatest reduction.
Wei Cai, Isabelle Maronde, Sophie Köndgen, Barbara Biere, Silke Buda, Brunhilde Schweiger, Doreen Staat, Walter Haas, Ekkehard Schuler, Virologic SARI Surveillance Study Group, Thorsten Wolff, Ralf Dürrwald, Djin‐Ye Oh, Kristin Tolksdorf, Janine Reiche   +14 more
wiley   +1 more source

Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

, 2023
BACKGROUND: Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season.
Greenough, Anne, Papenburg, Jesse, Keller, Christian, Pernica, Jeffrey M., Chi, Hsin, Clement, Pascale, Ahani, Bahar, Gupta, Atul, Kelly, Elizabeth J., Tuffy, Kevin M., Stein, Renato T., Aksyuk, Anastasia A., Danilenko, Daria M., Laubscher, Matt, Morehouse, Christopher, Hashimoto, Koichi, Wadia, Ushma, Richmond, Peter, Cohen, Robert, Lumertz, Magali, Heikkinen, Terho, Abram, Michael E., Yun, Ki Wook, Esser, Mark T., Choi, Eun Hwa, Palomino, María Angélica, Baraldi, Eugenio, Hosoya, Mitsuaki, de Los Santos, Abiel Homero Mascareñas, Rivero-Calle, Irene, Verwey, Charl, Komissarova, Kseniya, Wilkins, Deidre, Martinón-Torres, Federico, Kragten-Tabatabaie, Leyla, Gopalakrishnan, Vancheswaran, Chen, Albert Tian, Priante, Elena, Langedijk, Annefleur C., Nunes, Marta C., Tabor, David E., Brady, Tyler, Lebbink, Robert Jan, Bont, Louis J.   +43 more
core   +2 more sources

Impact of the 2025 New South Wales Respiratory Syncytial Virus Prevention Program on Infant Notifications and Hospitalisations: A Population‐Based Analysis

Medical Journal of Australia, Volume 224, Issue 6, June 2026.
ABSTRACT The 2025 NSW RSV Prevention Program, which achieved an estimated coverage of 63% maternal vaccination and 18% for infant immunisation, led to more than 40% reduction in RSV notifications and hospitalisations among infants aged younger than 6 months.
Janaki Amin, Sally L. Ellis, Christopher Lambeth, Jessica Gugusheff, Christine Selvey   +4 more
wiley   +1 more source